Coronary artery disease (CAD) is the most common cardiovascular disease, and it may manifest as a stable form or an acute coronary syndrome. Due to the aging of the population, the prevalence of this chronic disease is on the rise. The primary pathological processes are atherosclerosis and atherothrombosis. Antiplatelet therapy is part of the therapy from the time of diagnosis lifelong. It is part of the treatment of patients with various and changing comorbidities and also requires modification in the peri-interventional and perioperative periods. Progress in the development of antiplatelet therapy is remarkable. The availability of drugs with different mechanisms of action and different intensity of platelet reactivity inhibition allows the treatment to be balanced according to the patient's current thrombotic and bleeding risk.
This Research Topic is devoted to individualizing antiplatelet therapy in patients with CAD. The need for therapy personalization is related to the different and changing risks of thrombosis and bleeding over the patient life course. Determining the degree of both risks is based mainly on assessing clinical characteristics. Risk scores also include laboratory parameters (presence of anemia, thrombocytopenia, renal function) and procedural aspects in patients after percutaneous coronary intervention . The research article collection focuses on new targets of antiplatelet therapy and the escalation or de-escalation of therapy to personalize treatment efficacy and safety. The goal of this collection is to present a comprehensive view of the issue of individualizing antiplatelet therapy in patients with CAD and to highlight the current evidence to a wide readership.
The articles dedicated to the research area will provide an overview of the need and possibilities of individualizing antiplatelet therapy in the current knowledge and available evidence. The importance of risk stratification opens up a wide range of clinical and preclinical research opportunities. Articles focusing on new markers that predict thrombosis and bleeding risk are welcome in this context. The use of laboratory-determined efficacy of antiplatelet therapy is still an open issue. An essential aspect resonating in this issue is the importance of ethnicity in selecting the appropriate treatment. Articles with an interdisciplinary (anaesthesiology, geriatrics, neurology, etc.) overlap of the research topic are beneficial for clinical practice. The topic is broadly conceived and focused on clinical and preclinical research.
Coronary artery disease (CAD) is the most common cardiovascular disease, and it may manifest as a stable form or an acute coronary syndrome. Due to the aging of the population, the prevalence of this chronic disease is on the rise. The primary pathological processes are atherosclerosis and atherothrombosis. Antiplatelet therapy is part of the therapy from the time of diagnosis lifelong. It is part of the treatment of patients with various and changing comorbidities and also requires modification in the peri-interventional and perioperative periods. Progress in the development of antiplatelet therapy is remarkable. The availability of drugs with different mechanisms of action and different intensity of platelet reactivity inhibition allows the treatment to be balanced according to the patient's current thrombotic and bleeding risk.
This Research Topic is devoted to individualizing antiplatelet therapy in patients with CAD. The need for therapy personalization is related to the different and changing risks of thrombosis and bleeding over the patient life course. Determining the degree of both risks is based mainly on assessing clinical characteristics. Risk scores also include laboratory parameters (presence of anemia, thrombocytopenia, renal function) and procedural aspects in patients after percutaneous coronary intervention . The research article collection focuses on new targets of antiplatelet therapy and the escalation or de-escalation of therapy to personalize treatment efficacy and safety. The goal of this collection is to present a comprehensive view of the issue of individualizing antiplatelet therapy in patients with CAD and to highlight the current evidence to a wide readership.
The articles dedicated to the research area will provide an overview of the need and possibilities of individualizing antiplatelet therapy in the current knowledge and available evidence. The importance of risk stratification opens up a wide range of clinical and preclinical research opportunities. Articles focusing on new markers that predict thrombosis and bleeding risk are welcome in this context. The use of laboratory-determined efficacy of antiplatelet therapy is still an open issue. An essential aspect resonating in this issue is the importance of ethnicity in selecting the appropriate treatment. Articles with an interdisciplinary (anaesthesiology, geriatrics, neurology, etc.) overlap of the research topic are beneficial for clinical practice. The topic is broadly conceived and focused on clinical and preclinical research.